Update on drug management of refractory epilepsy in tuberous sclerosis complex

E van der Poest Clement, FE Jansen, KPJ Braun… - Pediatric Drugs, 2020 - Springer
Tuberous sclerosis complex (TSC) is a genetic neurocutaneous disorder with epilepsy as a
common and early presenting symptom. The neurological phenotype, however, is variable …

Design and mechanism of GABA aminotransferase inactivators. Treatments for epilepsies and addictions

RB Silverman - Chemical reviews, 2018 - ACS Publications
When the brain concentration of the inhibitory neurotransmitter γ-aminobutyric acid (GABA)
diminishes below a threshold level, the excess neuronal excitation can lead to convulsions …

Progress report on new antiepileptic drugs: A summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). I. Drugs in preclinical …

M Bialer, SI Johannessen, MJ Koepp, RH Levy… - …, 2018 - Wiley Online Library
Summary The Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT
XIV) took place in Madrid, Spain, on May 13‐16, 2018 and was attended by 168 delegates …

Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review

MJ Maguire, K Hemming, JM Wild, JL Hutton… - …, 2010 - Wiley Online Library
Purpose: Vigabatrin is an efficacious antiepileptic drug licensed as add‐on therapy in
refractory epilepsy and used in infantile spasms. Eight years after licensing, there emerged a …

Design and Mechanism of (S)-3-Amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic Acid, a Highly Potent γ-Aminobutyric Acid Aminotransferase Inactivator for …

JI Juncosa, K Takaya, HV Le… - Journal of the …, 2018 - ACS Publications
γ-Aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the central nervous
system. Inhibition of GABA aminotransferase (GABA-AT), a pyridoxal 5′-phosphate (PLP) …

Does vigabatrin treatment for infantile spasms cause visual field defects? An international multicentre study

R Riikonen, Z Rener‐Primec, L Carmant… - … Medicine & Child …, 2015 - Wiley Online Library
Aim The aim of this study was to examine whether vigabatrin treatment had caused visual
field defects (VFD s) in children of school age who had received the drug in infancy. Method …

Treatment of epileptic encephalopathies

A McTague, JH Cross - CNS drugs, 2013 - Springer
Epileptic encephalopathy is defined as a condition where the epileptic activity itself may
contribute to the severe neurological and cognitive impairment seen, over and above that …

OV329, a novel highly potent γ‐aminobutyric acid aminotransferase inactivator, induces pronounced anticonvulsant effects in the pentylenetetrazole seizure threshold …

M Feja, S Meller, LS Deking, E Kaczmarek… - …, 2021 - Wiley Online Library
Objective An attractive target to interfere with epileptic brain hyperexcitability is the
enhancement of γ‐aminobutyric acidergic (GABAergic) inhibition by inactivation of the GABA …

Epileptic syndromes and their treatment

CP Panayiotopoulos - Neonatal seizures. Second edition. London, 2007 - Springer
I would also like to thank Ian Stoneham, Publisher, and his team, particularly Hannah Cole
and Nadine Lemmens, Editors, and Keith Baker, Designer; their professionalism, dedication …

Sustained Inhibition of GABA-AT by OV329 Enhances Neuronal Inhibition and Prevents Development of Benzodiazepine Refractory Seizures

PLW Colmers, MN Arshad, J Mukherjee, S Lin, SFJ Ng… - eneuro, 2024 - eneuro.org
γ-Aminobutyric acid (GABA) is the principal inhibitory neurotransmitter in the adult brain
which mediates its rapid effects on neuronal excitability via ionotropic GABAA receptors …